» Articles » PMID: 36365220

Dual Functionalized Liposomes for Selective Delivery of Poorly Soluble Drugs to Inflamed Brain Regions

Abstract

Dual functionalized liposomes were developed to cross the blood−brain barrier (BBB) and to release their cargo in a pathological matrix metalloproteinase (MMP)-rich microenvironment. Liposomes were surface-functionalized with a modified peptide deriving from the receptor-binding domain of apolipoprotein E (mApoE), known to promote cargo delivery to the brain across the BBB in vitro and in vivo; and with an MMP-sensitive moiety for an MMP-triggered drug release. Different MMP-sensitive peptides were functionalized at both ends with hydrophobic stearate tails to yield MMP-sensitive lipopeptides (MSLPs), which were assembled into mApoE liposomes. The resulting bi-functional liposomes (i) displayed a < 180 nm diameter with a negative ζ-potential; (ii) were able to cross an in vitro BBB model with an endothelial permeability of 3 ± 1 × 10−5 cm/min; (iii) when exposed to functional MMP2 or 9, efficiently released an encapsulated fluorescein dye; (iv) showed high biocompatibility when tested in neuronal cultures; and (v) when loaded with glibenclamide, a drug candidate with poor aqueous solubility, reduced the release of proinflammatory cytokines from activated microglial cells.

Citing Articles

Double Peptide-Functionalized Carboxymethyl Chitosan-Coated Liposomes Loaded with Dexamethasone as a Potential Strategy for Active Targeting Drug Delivery.

Iftode L, Cadinoiu A, Rata D, Atanase L, Vochita G, Radulescu L Int J Mol Sci. 2025; 26(3).

PMID: 39940692 PMC: 11816442. DOI: 10.3390/ijms26030922.


A novel, glutathione-activated prodrug of pimasertib loaded in liposomes for targeted cancer therapy.

Amenta A, Comi S, Kravicz M, Sesana S, Antoniou A, Passarella D RSC Med Chem. 2024; .

PMID: 39430954 PMC: 11485093. DOI: 10.1039/d4md00517a.


Glibenclamide-Loaded Engineered Nanovectors (GNVs) Modulate Autophagy and NLRP3-Inflammasome Activation.

Saresella M, Zoia C, La Rosa F, Bazzini C, Sala G, Grassenis E Pharmaceuticals (Basel). 2023; 16(12).

PMID: 38139851 PMC: 10747596. DOI: 10.3390/ph16121725.


Glibenclamide-Loaded Nanoparticles Reduce NLRP3 Inflammasome Activation and Modulate miR-223-3p/miR-7-1-5p Expression in THP-1 Cells.

Mancuso R, Citterio L, Agostini S, Marventano I, La Rosa F, Re F Pharmaceuticals (Basel). 2023; 16(11).

PMID: 38004455 PMC: 10675475. DOI: 10.3390/ph16111590.


Raman Spectroscopy Characterization of Multi-Functionalized Liposomes as Drug-Delivery Systems for Neurological Disorders.

Roda F, Picciolini S, Mangolini V, Gualerzi A, Seneci P, Renda A Nanomaterials (Basel). 2023; 13(4).

PMID: 36839067 PMC: 9962107. DOI: 10.3390/nano13040699.

References
1.
Zhang L, Robertson C, Green B, Pruess T, White H, Bulaj G . Structural requirements for a lipoamino acid in modulating the anticonvulsant activities of systemically active galanin analogues. J Med Chem. 2009; 52(5):1310-6. PMC: 2765488. DOI: 10.1021/jm801397w. View

2.
Jin Y, Wu Z, Wu C, Zi Y, Chu X, Liu J . Size-adaptable and ligand (biotin)-sheddable nanocarriers equipped with avidin scavenging technology for deep tumor penetration and reduced toxicity. J Control Release. 2020; 320:142-158. DOI: 10.1016/j.jconrel.2020.01.040. View

3.
Nakayama S, Taguchi N, Isaka Y, Nakamura T, Tanaka M . Glibenclamide and Therapeutic Hypothermia Have Comparable Effect on Attenuating Global Cerebral Edema Following Experimental Cardiac Arrest. Neurocrit Care. 2017; 29(1):119-127. DOI: 10.1007/s12028-017-0479-3. View

4.
Abdul-Gader A, Miles A, Wallace B . A reference dataset for the analyses of membrane protein secondary structures and transmembrane residues using circular dichroism spectroscopy. Bioinformatics. 2011; 27(12):1630-6. DOI: 10.1093/bioinformatics/btr234. View

5.
Arrua E, Hartwig O, Ho D, Loretz B, Murgia X, Salomon C . Surfactant-Free Glibenclamide Nanoparticles: Formulation, Characterization and Evaluation of Interactions with Biological Barriers. Pharm Res. 2021; 38(6):1081-1092. DOI: 10.1007/s11095-021-03056-2. View